Ovo

Ovo Labs is a private German biotech company developing therapeutics to improve human egg quality and increase the success of in vitro fertilization. The company was founded in 2025 as a spin-out from the Max Planck Institute for Multidisciplinary Sciences and is building drug candidates intended to reduce age-related defects in oocytes and extend reproductive longevity. Its lead portfolio consists of three preclinical EmbryoProtect programs aimed at improving fertility outcomes and lowering chromosomal abnormalities in eggs. Ovo Labs operates in reproductive medicine and women's health, combining translational fertility biology with drug development for use alongside standard IVF workflows.